Market Research Reports

Biosimilars Market - Global And China Forecast, Share, Size, Growth And Industry Analysis (2010 - 2017)

 

Description




Description

Biosimilars or follow-on biologics are copies of biological drugs (biopharmaceuticals). Biosimilars provide significant cost saving to both the users and the industry hence the adoption of these drugs are expected to be higher side. However, the debate on the interest of original biopharmaceutical developer and stability of copied drug has raised controversies across the globe. 

Meanwhile low entry barriers and absence of clear regulatory norms for biological drugs and non-approval of follow-on biologics in the U.S. market; has prompted pharmaceutical companies to turn towards emerging markets such as India and countries in the South-East Asia. 

The report contains the global scenario of Biosimilars market discussing detailed overview and market figures. The research report analyses the industry growth rate, industry capacity, and industry structure. The report analyses the historical data and forecasts the Biosimilars market size, production forecasts along with key factors driving and restraining the market.

This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include 
  • North America 
  • Asia Pacific 
  • Europe
  • Rest of the World  
This report provides comprehensive analysis of 
  • Market growth drivers 
  • Factors limiting market growth
  • Current market trends 
  • Market structure
  • Market projections for upcoming years 
This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis. 

Reasons for Buying this Report
  • This report provides pin-point analysis for changing competitive dynamics
  • It provides a forward looking perspective on different factors driving or restraining market growth 
  • It provides a technological growth map over time to understand the industry growth rate
  • It provides a seven-year forecast assessed on the basis of how the market is predicted to grow 
  • It helps in understanding the key product segments and their future
  • It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
  • It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments 
  • It provides distinctive graphics and exemplified SWOT analysis of major market segments

Table of Contents




TABLE OF CONTENTS

1) INTRODUCTION
 1.1 Objective of the Research
 1.2 Report Highlights
 1.3 Scope of the Report
 1.4 Research Methodology

2) MARKET OUTLINE
2.1. Defining the global biosimilar market
2.2. Driving factor analysis
2.2.1. Demand and Supply-side drivers
2.2.2. Restraints & opportunities
2.2.3. Key points
2.3. Issues related with biosimilar
2.4. Potential matrix for global biosimilar 
2.4.1. Products
2.4.2. Applications
2.5. Biosimilar market dynamics
2.6. Pricing of biosimilar drug
2.7. Biosimilar products geographical trend

3) BIOSIMILAR PRODUCTS MARKET
3.1. Recombinant glycosylated proteins
3.1.1. Drivers & restraints
3.1.2. Erythropoietin (EPO)
3.1.3. Urokinase
3.1.4. Glucocerebrosidase
3.1.5. Monoclonal antibodies
3.1.5.1. Chimaeric antibodies
3.1.5.2. Humanized / cdr-grafted / reshaped antibodies
3.1.5.3. Human antibodies and fusion protein
3.1.6. Follitropin
3.1.7. Thyrotropin
3.1.8. Becaplermin
3.1.9. Granulocyte-macrophage-CSF (GM-CSF)
3.1.10. Recombinant Human DNASE (RHDNASE)
3.1.11. Factor VIIA
3.1.11.1. Factor VIII
3.1.11.2. Factor IX
3.1.12. Activated protein-c
3.1.13. Tissue plasminogen activator
3.2. Recombinant non-glycosylated protein
3.2.1. Drivers and restraints
3.2.2. Insulin
3.2.2.1. Drivers & restraints
3.2.2.2. Opportunities
3.2.3. Interferons
3.2.3.1. Interferon alfa
3.2.3.2. Interferon beta-1a
3.2.3.3. Interferon gamma
3.2.4. Recombinant human growth hormone
3.2.5. Lepirudin
3.2.6. Interleukin-11
3.2.7. Anakinra
3.2.8. Interleukin – 2 (Il-2)
3.2.9. Granulocyte colony-stimulating factor (G-CSF)
3.3. Peptides
3.3.1. Drivers
3.3.2. Restraints & opportunities
3.3.3. Cyclosporine
3.3.4. Calcitonin
3.3.5. Bivalirudin
3.3.6. Enfuvirtide
3.3.7. Glucagon
3.3.8. Eptifibatide
3.3.9. Octreotide
3.3.10. Desmopressin
3.3.11. LH-RH (Leuprolide)
3.3.12. Nesiritide
3.3.13. Teriparatide

4) BIOSIMILAR TECHNOLOGY
4.1. Recombinant DNA technology (RDNA technology)
4.1.1. Drivers
4.1.2. Restraints & opportunities
4.2. Chromatography
4.2.1. Drivers & opportunities
4.2.2. Top player analysis
4.2.3. Liquid chromatography (LC)
4.2.4. Gas chromatography (GC)
4.3. Bioassay
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Techniques in bioassay
4.3.3.1. Six point assay
4.3.3.2. Multiple point assays
4.3.3.3. Interpolation method
4.3.3.4. Bracketing method
4.3.3.5. Matching bioassays
4.4. Monoclonal antibodies (MAB) technology
4.4.1. Drivers
4.4.2. Restraints & opportunities
4.4.3. Top player analysis
4.5. Western blotting
4.5.1. Drivers
4.5.2. Restraints & opportunities
4.6. Protein sequencing
4.6.1. Drivers
4.6.2. Restraints & opportunities
4.7. Nuclear magnetic resonance (NMR) technology
4.7.1. Drivers
4.7.2. Restraints & opportunities
4.8. Electrophoresis
4.8.1. Drivers
4.8.2. Restraints & opportunities
4.8.3. GEL electrophoresis
4.8.4. Capillary electrophoresis
4.9. Mass spectrometry
4.9.1. Drivers
4.9.2. Restraints

5) BIOSIMILAR APPLICATION MARKET
5.1. Introduction
5.1.1. Drivers
5.1.2. Restraints
5.2. Oncology
5.2.1. Drivers
5.2.2. Restraints & opportunities
5.2.3. Lung cancer
5.2.4. Colorectal cancer
5.2.5. Breast cancer
5.2.6. Cervical cancer
5.2.7. Leukemia
5.2.7.1. Drivers
5.2.8. Prostate cancer
5.3. Infectious diseases
5.3.1. HIV/Aids
5.3.1.1. Drivers
5.3.2. Hepatitis B
5.3.3. Hepatitis C
5.4. Chronic and autoimmune diseases
5.4.1. Diabetes
5.4.1.1. Drivers
5.4.2. Neutropenia
5.4.3. Multiple sclerosis
5.4.3.1. Drivers
5.4.3.2. Inhibitors and opportunities
5.4.4. Cystic fibrosis
5.4.5. Rheumatoid arthritis (RA)
5.4.5.1. Drivers
5.4.5.2. Restraints
5.4.6. Acromegaly
5.4.6.1. Driver
5.4.7. Leprosy
5.5. Hematology
5.5.1. Drivers
5.5.2. Chemotherapy induced anemia
5.5.2.1. Drivers
5.5.2.2. Restraints and opportunities
5.5.3. Hemophilia
5.5.4. Pulmonary embolism
5.5.4.1. Drivers
5.6. Growth hormone deficiency (GHD)
5.6.1. Drivers
5.7. Other diseases
5.7.1. Gaucher disease
5.7.2. Osteoporosis
5.7.3. Fertility disorders (Infertility)
5.7.4. Skin ulcer
5.7.5. Hypoglycemia
5.7.6. Nocturnal enuresis
5.7.7. Congestive heart failure (CHF)
5.7.8. Systemic sepsis
5.7.9. Others

6) BIOSIMILAR SERVICE MARKET
6.1. Clinical trials
6.1.1. Drivers & restraints
6.1.2. Phase I
6.1.3. Phase II
6.1.4. Phase III
6.2. Contract research and manufacturing services
6.2.1. Drivers
6.2.2. Restraints & opportunities

7) GEOGRAPHIC ANALYSIS
7.1. North America biosimilar market
7.2. EMEA biosimilar market
7.3. Asia-Pacific biosimilar market
7.4. Latin America Biosimilars market

8) COMPANY PROFILES
8.1.1. Teva
8.1.2. Sandoz
8.1.3. Hospira
8.1.4. Mylan
8.1.5. Actavis
8.1.6. Biocon Ltd.
8.1.7. Cipla Ltd.
8.1.8. Dr. Reddy's Laboratories Ltd.
8.1.9. Wockhardt Ltd
8.1.10. Stada Arzneimittel AG

Enquiry Before Buying




 
Pre Book Price: $4315.5 Original Price: $4795
Share This Market Study!  

Upcoming Report

Payment
Copyright @ Transparency Market Research